Citations (94)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Shivam Nishad, Rupa Mazumder, Swarupanjali Padhi, Malakapogu Ravindra Basu & Pratibha Pandey. (2023) Enhancement of bioavailability of therapeutics using drug conjugation approach: an in-depth review. International Journal of Polymeric Materials and Polymeric Biomaterials 0:0, pages 1-16.
Read now
Read now
Hanlan Liu, Jayaprakasam Bolleddula, Andrew Nichols, Lei Tang, Zhiyang Zhao & Chandra Prakash. (2020) Metabolism of bioconjugate therapeutics: why, when, and how?. Drug Metabolism Reviews 52:1, pages 66-124.
Read now
Read now
Muhammad Kalim, Jie Chen, Shenghao Wang, Caiyao Lin, Saif Ullah, Keying Liang, Qian Ding, Shuqing Chen & Jinbiao Zhan. (2017) Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates. Drug Design, Development and Therapy 11, pages 2265-2276.
Read now
Read now
Jogender Tushir-Singh. (2017) Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy. Expert Opinion on Biological Therapy 17:3, pages 325-338.
Read now
Read now
Lucy Yan Pan, Oscar Salas-Solano & John F. Valliere-Douglass. (2017) Localized conformational interrogation of antibody and antibody-drug conjugates by site-specific carboxyl group footprinting. mAbs 9:2, pages 307-318.
Read now
Read now
Linlin Jiang, Ming Yang, Xiaoyun Zhang, Shiqi Bao, Li Ma, Dongmei Fan, Yuan Zhou, Dongsheng Xiong & Yongsu Zhen. (2016) A novel antibody–drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity. Journal of Drug Targeting 24:1, pages 47-57.
Read now
Read now
Muhammad Sajid Hamid Akash, Kanwal Rehman, Amna Parveen & Muhammad Ibrahim. (2016) Antibody-drug conjugates as drug carrier systems for bioactive agents. International Journal of Polymeric Materials and Polymeric Biomaterials 65:1, pages 1-10.
Read now
Read now
E Michael Lewiecki. (2015) Biological therapy: chronicling 15 years of progress. Expert Opinion on Biological Therapy 15:5, pages 619-621.
Read now
Read now
Gordana Maric, April AN Rose, Matthew G Annis & Peter M Siegel. (2013) Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. OncoTargets and Therapy 6, pages 839-852.
Read now
Read now
Domenico Mavilio, Lorenzo Galluzzi & Enrico Lugli. (2013) Novel multifunctional antibody approved for the treatment of breast cancer. OncoImmunology 2:3.
Read now
Read now
Domenico Ribatti, Girolamo Ranieri, Antonio Basile, Amalia Azzariti, Angelo Paradiso & Angelo Vacca. (2012) Tumor endothelial markers as a target in cancer. Expert Opinion on Therapeutic Targets 16:12, pages 1215-1225.
Read now
Read now
Articles from other publishers (83)
Ritwik Maiti, Bhumika Patel, Nrupesh Patel, Mehul Patel, Alkesh Patel & Nirav Dhanesha. (2023) Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities. Archives of Pharmacal Research 46:5, pages 361-388.
Crossref
Crossref
Sonia Eligini, Erica Gianazza, Alice Mallia, Stefania Ghilardi & Cristina Banfi. (2023) Macrophage Phenotyping in Atherosclerosis by Proteomics. International Journal of Molecular Sciences 24:3, pages 2613.
Crossref
Crossref
Mo Wu, Wei Huang, Nan Yang & Yanyong Liu. (2022) Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy. Experimental Hematology & Oncology 11:1.
Crossref
Crossref
Iván Cheng-Sánchez, Federico Moya-Utrera, Cristina Porras-Alcalá, Juan M. López-Romero & Francisco Sarabia. (2022) Antibody-Drug Conjugates Containing Payloads from Marine Origin. Marine Drugs 20:8, pages 494.
Crossref
Crossref
Zhiwen Fu, Shijun Li, Sifei Han, Chen Shi & Yu Zhang. (2022) Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Xinling Zhang, Andrew C Huang, Fahai Chen, Hu Chen, Lele Li, Nana Kong, Wenting Luo & Jianmin Fang. (2022) Novel development strategies and challenges for anti-Her2 antibody-drug conjugates. Antibody Therapeutics 5:1, pages 18-29.
Crossref
Crossref
Yiming Jin, Megan A. Schladetsch, Xueting Huang, Marcy J. Balunas & Andrew J. Wiemer. (2022) Stepping forward in antibody-drug conjugate development. Pharmacology & Therapeutics 229, pages 107917.
Crossref
Crossref
Robert S. Foti. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
716
742
.
Andrew P Mayer, Hermes Licea-Perez, Sharon Boram, Kristen E Pannullo, Jonathan Kehler & Christopher A Evans. (2021) Overcoming challenges associated with the bioanalysis of cysteine-conjugated metabolites in the presence of antibody–drug conjugates. Bioanalysis 13:18, pages 1427-1439.
Crossref
Crossref
Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. CaimiErin Reid, Owen A. O’ConnorJay M. FeingoldKirit M. ArdeshnaWilliam TownsendMelhem SolhLeonard T. HeffnerDavid UngarLuqiang WangJoseph BoniKarin Havenith, Yajuan QinBrad S. Kahl. (2021) Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood 137:19, pages 2634-2645.
Crossref
Crossref
Stephen J. Walsh, Jonathan D. Bargh, Friederike M. Dannheim, Abigail R. Hanby, Hikaru Seki, Andrew J. Counsell, Xiaoxu Ou, Elaine Fowler, Nicola Ashman, Yuri Takada, Albert Isidro-Llobet, Jeremy S. Parker, Jason S. Carroll & David R. Spring. (2021) Site-selective modification strategies in antibody–drug conjugates. Chemical Society Reviews 50:2, pages 1305-1353.
Crossref
Crossref
Narendranath Epperla & Mehdi Hamadani. (2021) A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine. Current Hematologic Malignancy Reports 16:1, pages 19-24.
Crossref
Crossref
Guillaume Sicard, Clément Paris, Sarah Giacometti, Anne Rodallec, Joseph Ciccolini, Palma Rocchi & Raphaëlle Fanciullino. (2020) Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer. Pharmaceutics 12:12, pages 1166.
Crossref
Crossref
Maria K. Skytthe, Jonas Heilskov Graversen & Søren K. Moestrup. (2020) Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases. International Journal of Molecular Sciences 21:15, pages 5497.
Crossref
Crossref
Alessandra Castegna, Rosanna Gissi, Alessio Menga, Monica Montopoli, Maria Favia, Antonella Viola & Marcella Canton. (2020) Pharmacological targets of metabolism in disease: Opportunities from macrophages. Pharmacology & Therapeutics 210, pages 107521.
Crossref
Crossref
Madhuri Jayathirtha & Costel C. Darie. 2019. Advancements of Mass Spectrometry in Biomedical Research. Advancements of Mass Spectrometry in Biomedical Research
251
263
.
Naresh Goli, Pradeep Kumar Bolla & Venu Talla. (2018) Antibody-drug conjugates (ADCs): Potent biopharmaceuticals to target solid and hematological cancers- an overview. Journal of Drug Delivery Science and Technology 48, pages 106-117.
Crossref
Crossref
Nafsika Forte, Vijay Chudasama & James R. Baker. (2018) Homogeneous antibody-drug conjugates via site-selective disulfide bridging. Drug Discovery Today: Technologies 30, pages 11-20.
Crossref
Crossref
Song Cho, Francesca Zammarchi, David G. Williams, Carin E.G. Havenith, Noel R. Monks, Peter Tyrer, Francois D'Hooge, Ryan Fleming, Kapil Vashisht, Nazzareno Dimasi, Francois Bertelli, Simon Corbett, Lauren Adams, Halla W. Reinert, Sandamali Dissanayake, Charles E. Britten, Wanda King, Karma Dacosta, Ravinder Tammali, Kevin Schifferli, Patrick Strout, Martin KoradeIIIIII, Mary Jane Masson Hinrichs, Simon Chivers, Eva Corey, He Liu, Sae Kim, Neil H. Bander, Philip W. Howard, John A. Hartley, Steve Coats, David A. Tice, Ronald Herbst & Patrick H. van Berkel. (2018) Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer. Molecular Cancer Therapeutics 17:10, pages 2176-2186.
Crossref
Crossref
Hadi Nasiri, Zahra Valedkarimi, Leili Aghebati‐Maleki & Jafar Majidi. (2018) Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy. Journal of Cellular Physiology 233:9, pages 6441-6457.
Crossref
Crossref
Mohammad A. Tabrizi, Isabel Figueroa, Wendy Blumenschein & Jeff Grein. 2018. Development of Antibody-Based Therapeutics. Development of Antibody-Based Therapeutics
197
206
.
Alexander V. LyubimovEugenia Kraynov & Steven W. Martin. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
22
.
Luis Mario Villela-Ma, Ana Karen Velez-Ayal, Rosa del Carmen Lopez-Sanc, Jorge A Martinez-C & Jose A Hernandez-. (2017) Advantages of Drug Selective Distribution in Cancer Treatment: Brentuximab Vedotin. International Journal of Pharmacology 13:7, pages 785-807.
Crossref
Crossref
Patrick J. Kennedy, Carla Oliveira, Pedro L. Granja & Bruno Sarmento. (2017) Antibodies and associates: Partners in targeted drug delivery. Pharmacology & Therapeutics 177, pages 129-145.
Crossref
Crossref
Kenneth R. Durbin, M. Shannon Nottoli, Nathaniel D. Catron, Nicole Richwine & Gary J. Jenkins. (2017) High-Throughput, Multispecies, Parallelized Plasma Stability Assay for the Determination and Characterization of Antibody–Drug Conjugate Aggregation and Drug Release. ACS Omega 2:8, pages 4207-4215.
Crossref
Crossref
Yongjun Xue, Priya Sriraman, Matthew V. Myers, Xiaomin Wang, Jian Chen, Brian Melo, Martha Vallejo, Stephen E. Maxwell & Sekhar Surapaneni. 2017. Protein Analysis using Mass Spectrometry. Protein Analysis using Mass Spectrometry
183
201
.
Xiuling Li, Christopher G. Nelson, Rajesh R. Nair, Lori Hazlehurst, Tina Moroni, Pablo Martinez-Acedo, Alex R. Nanna, David Hymel, Terrence R. BurkeJr.Jr. & Christoph Rader. (2017) Stable and Potent Selenomab-Drug Conjugates. Cell Chemical Biology 24:4, pages 433-442.e6.
Crossref
Crossref
Yu-Jie Wang, Yu-Yan Li, Xiao-Yu Liu, Xiao-Ling Lu, Xin Cao & Bing-Hua Jiao. (2017) Marine Antibody–Drug Conjugates: Design Strategies and Research Progress. Marine Drugs 15:1, pages 18.
Crossref
Crossref
María Isabel Lucío, Roberta Opri, Marcella Pinto, Alessia Scarsi, Jose L. G. Fierro, Moreno Meneghetti, Giulio Fracasso, Maurizio Prato, Ester Vázquez & María Antonia Herrero. (2017) Targeted killing of prostate cancer cells using antibody–drug conjugated carbon nanohorns. Journal of Materials Chemistry B 5:44, pages 8821-8832.
Crossref
Crossref
João P. M. Nunes, Vessela Vassileva, Eifion Robinson, Maurício Morais, Mark E. B. Smith, R. Barbara Pedley, Stephen Caddick, James R. Baker & Vijay Chudasama. (2017) Use of a next generation maleimide in combination with THIOMAB™ antibody technology delivers a highly stable, potent and near homogeneous THIOMAB™ antibody-drug conjugate (TDC). RSC Advances 7:40, pages 24828-24832.
Crossref
Crossref
Maurício Morais, João P. M. Nunes, Kersti Karu, Nafsika Forte, Irene Benni, Mark E. B. Smith, Stephen Caddick, Vijay Chudasama & James R. Baker. (2017) Optimisation of the dibromomaleimide (DBM) platform for native antibody conjugation by accelerated post-conjugation hydrolysis. Organic & Biomolecular Chemistry 15:14, pages 2947-2952.
Crossref
Crossref
Michael Adamo, Guoyong Sun, Difei Qiu, Joseph Valente, Wenkui Lan, Hangtian Song, Mark Bolgar, Amit Katiyar & Girija Krishnamurthy. (2017) Drug-to-antibody determination for an antibody-drug-conjugate utilizing cathepsin B digestion coupled with reversed-phase high-pressure liquid chromatography analysis. Journal of Chromatography A 1481, pages 44-52.
Crossref
Crossref
Xiuling Li & Christoph Rader. 2017. Synthetic Antibodies. Synthetic Antibodies
145
164
.
Kouhei Tsumoto, Anthony Young & Satoshi Ohtake. 2016. Antibody‐Drug Conjugates. Antibody‐Drug Conjugates
105
129
.
Jay Harper & Robert Hollingsworth. 2016. Antibody‐Drug Conjugates. Antibody‐Drug Conjugates
33
58
.
Michael J. Flynn, Francesca Zammarchi, Peter C. Tyrer, Ayse U. Akarca, Narinder Janghra, Charles E. Britten, Carin E.G. Havenith, Jean-Noel Levy, Arnaud Tiberghien, Luke A. Masterson, Conor Barry, Francois D'Hooge, Teresa Marafioti, Paul W.H.I. Parren, David G. Williams, Philip W. Howard, Patrick H. van Berkel & John A. Hartley. (2016) ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Molecular Cancer Therapeutics 15:11, pages 2709-2721.
Crossref
Crossref
Subash C. B. Gopinath, Thangavel Lakshmipriya, Yeng Chen, M. K. Md Arshad, Jesinda P. Kerishnan, A. R. Ruslinda, Yarub Al-Douri, C. H. Voon & Uda Hashim. (2016) Cell-targeting aptamers act as intracellular delivery vehicles. Applied Microbiology and Biotechnology 100:16, pages 6955-6969.
Crossref
Crossref
Benson Gikanga, Nia S. Adeniji, Thomas W. Patapoff, Hung-Wei Chih & Li Yi. (2016) Cathepsin B Cleavage of vcMMAE-Based Antibody–Drug Conjugate Is Not Drug Location or Monoclonal Antibody Carrier Specific. Bioconjugate Chemistry 27:4, pages 1040-1049.
Crossref
Crossref
Peng Zhan, Christophe Pannecouque, Erik De Clercq & Xinyong Liu. (2015) Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. Journal of Medicinal Chemistry 59:7, pages 2849-2878.
Crossref
Crossref
E. Kraynov, A. V. Kamath, M. Walles, E. Tarcsa, A. Deslandes, R. A. Iyer, A. Datta-Mannan, P. Sriraman, M. Bairlein, J. J. Yang, M. Barfield, G. Xiao, E. Escandon, W. Wang, D. A. Rock, N. V. Chemuturi & D. J. Moore. (2015) Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper. Drug Metabolism and Disposition 44:5, pages 617-623.
Crossref
Crossref
Roy van der Meel, Laurens J. C. Vehmeijer, Robbert Jan Kok, Gert Storm & Ethlinn V. B. van Gaal. 2016. Intracellular Delivery III. Intracellular Delivery III
163
200
.
Katie F. Maass, Chethana Kulkarni, Mohiuddin A. Quadir, Paula T. Hammond, Alison M. Betts & Karl Dane Wittrup. (2015) A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin. Journal of Pharmaceutical Sciences 104:12, pages 4409-4416.
Crossref
Crossref
Satish K. Singh, Donna L. Luisi & Roger H. Pak. (2015) Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability. Pharmaceutical Research 32:11, pages 3541-3571.
Crossref
Crossref
Rodrigo Vazquez-Lombardi, Tri Giang Phan, Carsten Zimmermann, David Lowe, Lutz Jermutus & Daniel Christ. (2015) Challenges and opportunities for non-antibody scaffold drugs. Drug Discovery Today 20:10, pages 1271-1283.
Crossref
Crossref
S. Sadekar, I. Figueroa & M. Tabrizi. (2015) Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection. The AAPS Journal 17:4, pages 828-836.
Crossref
Crossref
Jonas Graversen & Søren Moestrup. (2015) Drug Trafficking into Macrophages via the Endocytotic Receptor CD163. Membranes 5:2, pages 228-252.
Crossref
Crossref
Wayne Widdison, Sharon Wilhelm, Karen Veale, Juliet Costoplus, Gregory Jones, Charlene Audette, Barbara Leece, Laura Bartle, Yelena Kovtun & Ravi Chari. (2015)
Metabolites of Antibody–Maytansinoid Conjugates: Characteristics and
in Vitro
Potencies
. Molecular Pharmaceutics 12:6, pages 1762-1773.
Crossref
Crossref
Antoine Maruani, Mark E.B. Smith, Enrique Miranda, Kerry A. Chester, Vijay Chudasama & Stephen Caddick. (2015) A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. Nature Communications 6:1.
Crossref
Crossref
Madduri Srinivasarao, Chris V. Galliford & Philip S. Low. (2015) Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nature Reviews Drug Discovery 14:3, pages 203-219.
Crossref
Crossref
Debmalya Bhunia, Rajdeep Chowdhury, Kankan Bhattacharyya & Surajit Ghosh. (2015) Fluorescence fluctuation of an antigen–antibody complex: circular dichroism, FCS and smFRET of enhanced GFP and its antibody. Physical Chemistry Chemical Physics 17:38, pages 25250-25259.
Crossref
Crossref
João P. M. Nunes, Maurício Morais, Vessela Vassileva, Eifion Robinson, Vineeth S. Rajkumar, Mark E. B. Smith, R. Barbara Pedley, Stephen Caddick, James R. Baker & Vijay Chudasama. (2015) Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody–drug conjugate (ADC). Chemical Communications 51:53, pages 10624-10627.
Crossref
Crossref
LeeRon Shefet-Carasso & Itai Benhar. (2015) Antibody-targeted drugs and drug resistance—Challenges and solutions. Drug Resistance Updates 18, pages 36-46.
Crossref
Crossref
Lukas Leder. 2015. Site-Specific Protein Labeling. Site-Specific Protein Labeling
7
27
.
Bérengère Vire, Martin Skarzynski, Joshua D. Thomas, Christopher G. Nelson, Alexandre David, Georg Aue, Terrence R. BurkeJrJr, Christoph Rader & Adrian Wiestner. (2014) Harnessing the Fcμ Receptor for Potent and Selective Cytotoxic Therapy of Chronic Lymphocytic Leukemia. Cancer Research 74:24, pages 7510-7520.
Crossref
Crossref
Thomas H. Pillow, Janet Tien, Kathryn L. Parsons-Reponte, Sunil Bhakta, Hao Li, Leanna R. Staben, Guangmin Li, Josefa Chuh, Aimee Fourie-O’Donohue, Martine Darwish, Victor Yip, Luna Liu, Douglas D. Leipold, Dian Su, Elmer Wu, Susan D. Spencer, Ben-Quan Shen, Keyang Xu, Katherine R. Kozak, Helga Raab, Richard Vandlen, Gail D. Lewis Phillips, Richard H. Scheller, Paul Polakis, Mark X. Sliwkowski, John A. Flygare & Jagath R. Junutula. (2014) Site-Specific Trastuzumab Maytansinoid Antibody–Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering. Journal of Medicinal Chemistry 57:19, pages 7890-7899.
Crossref
Crossref
Ali Azhdarinia & Sukhen Ghosh. 2014. Nanomedicine. Nanomedicine
31
74
.
Xiuru Li, Tao Fang & Geert‐Jan Boons. (2014) Preparation of Well‐Defined Antibody–Drug Conjugates through Glycan Remodeling and Strain‐Promoted Azide–Alkyne Cycloadditions. Angewandte Chemie International Edition 53:28, pages 7179-7182.
Crossref
Crossref
Xiuru Li, Tao Fang & Geert‐Jan Boons. (2014) Preparation of Well‐Defined Antibody–Drug Conjugates through Glycan Remodeling and Strain‐Promoted Azide–Alkyne Cycloadditions. Angewandte Chemie 126:28, pages 7307-7310.
Crossref
Crossref
Christoph Rader. (2014) Chemically programmed antibodies. Trends in Biotechnology 32:4, pages 186-197.
Crossref
Crossref
Lucy Yan Pan, Oscar Salas-Solano & John F. Valliere-Douglass. (2014) Conformation and Dynamics of Interchain Cysteine-Linked Antibody-Drug Conjugates as Revealed by Hydrogen/Deuterium Exchange Mass Spectrometry. Analytical Chemistry 86:5, pages 2657-2664.
Crossref
Crossref
Arvind Rajpal, Pavel Strop, Yik Andy Yeung, Javier Chaparro‐Riggers & Jaume Pons. 2014. Therapeutic Fc‐Fusion Proteins. Therapeutic Fc‐Fusion Proteins
1
44
.
Manuel Simon, Nikolas Stefan, Lubor Borsig, Andreas Plückthun & Uwe Zangemeister-Wittke. (2014) Increasing the Antitumor Effect of an EpCAM-Targeting Fusion Toxin by Facile Click PEGylation. Molecular Cancer Therapeutics 13:2, pages 375-385.
Crossref
Crossref
Xiangru Li, Rie Saeki, Akihiro Watari, Kiyohito Yagi & Masuo Kondoh. (2014) Tissue distribution and safety evaluation of a claudin-targeting molecule, the C-terminal fragment of Clostridium perfringens enterotoxin. European Journal of Pharmaceutical Sciences 52, pages 132-137.
Crossref
Crossref
Zhao Hui Li, Qian Zhang, Hai Bin Wang, Ya Nan Zhang, Ding Ding, Li Qiang Pan, David Miao, Shi Xu, Chen Zhang, Pei Hua Luo, Hua Naranmandura & Shu Qing Chen. (2013) Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin. Investigational New Drugs 32:1, pages 75-86.
Crossref
Crossref
John A. Hartley. 2014. Cancer Drug Design and Discovery. Cancer Drug Design and Discovery
479
490
.
Kewal K. JainKewal K. Jain. 2014. Applications of Biotechnology in Oncology. Applications of Biotechnology in Oncology
371
391
.
Monika Farys, Claire L. Ginn, George O. Badescu, Karolina Peciak, Estera M. Pawlisz, Hanieh Khalili & Steve J. Brocchini. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
52
.
Manuel Simon, Raphael Frey, Uwe Zangemeister-Wittke & Andreas Plückthun. (2013) Orthogonal Assembly of a Designed Ankyrin Repeat Protein–Cytotoxin Conjugate with a Clickable Serum Albumin Module for Half-Life Extension. Bioconjugate Chemistry 24:11, pages 1955-1966.
Crossref
Crossref
Bart Cornelissen, Andrew Waller, Sarah Able & Katherine A. Vallis. (2013) Molecular Radiotherapy Using Cleavable Radioimmunoconjugates That Target EGFR and γH2AX. Molecular Cancer Therapeutics 12:11, pages 2472-2482.
Crossref
Crossref
Roy van der Meel, Laurens J.C. Vehmeijer, Robbert J. Kok, Gert Storm & Ethlinn V.B. van Gaal. (2013) Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. Advanced Drug Delivery Reviews 65:10, pages 1284-1298.
Crossref
Crossref
Sumit Goswami, Wei Wang, Tsutomu Arakawa & Satoshi Ohtake. (2013) Developments and Challenges for mAb-Based Therapeutics. Antibodies 2:4, pages 452-500.
Crossref
Crossref
Prabodhika MallikaratchyJeffery GardnerLars Ulrik R. NordstrømNicholas J. VeomettMichael R. McDevittMark L. HeaneyDavid A. Scheinberg. (2013) A Self-Assembling Short Oligonucleotide Duplex Suitable for Pretargeting. Nucleic Acid Therapeutics 23:4, pages 289-299.
Crossref
Crossref
Loretta Sullivan-Chang, Robert T. O’Donnell & Joseph M. Tuscano. (2013) Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook. BioDrugs 27:4, pages 293-304.
Crossref
Crossref
Han Han & Mark E. Davis. (2013) Single-Antibody, Targeted Nanoparticle Delivery of Camptothecin. Molecular Pharmaceutics 10:7, pages 2558-2567.
Crossref
Crossref
Hayley Pye, Ioanna Stamati, Gokhan Yahioglu, M. Butt & Mahendra Deonarain. (2013) Antibody-Directed Phototherapy (ADP). Antibodies 2:4, pages 270-305.
Crossref
Crossref
Hendrik Fuchs, Christopher Bachran & David Flavell. (2013) Diving through Membranes: Molecular Cunning to Enforce the Endosomal Escape of Antibody-Targeted Anti-Tumor Toxins. Antibodies 2:4, pages 209-235.
Crossref
Crossref
Katherine Griffiths, Olan Dolezal, Kathy Parisi, Julie Angerosa, Con Dogovski, Miles Barraclough, Abdulmonem Sanalla, Joanne Casey, Iveth González, Matthew Perugini, Stewart Nuttall & Michael Foley. (2013) Shark Variable New Antigen Receptor (VNAR) Single Domain Antibody Fragments: Stability and Diagnostic Applications. Antibodies 2:4, pages 66-81.
Crossref
Crossref
Ka-To Shum, Jiehua Zhou & John J. Rossi. (2013) Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma. Journal of Cancer Therapy 04:04, pages 872-890.
Crossref
Crossref
Dimitrios Vlachakis & Sophia Kossida. (2013) Antibody Drug Conjugate Bioinformatics: Drug Delivery through the Letterbox. Computational and Mathematical Methods in Medicine 2013, pages 1-4.
Crossref
Crossref
John A. Flygare, Thomas H. Pillow & Paul Aristoff. (2013) Antibody-Drug Conjugates for the Treatment of Cancer. Chemical Biology & Drug Design 81:1, pages 113-121.
Crossref
Crossref
Lourdes Castañeda, Antoine Maruani, Felix F. Schumacher, Enrique Miranda, Vijay Chudasama, Kerry A. Chester, James R. Baker, Mark E. B. Smith & Stephen Caddick. (2013) Acid-cleavable thiomaleamic acid linker for homogeneous antibody–drug conjugation. Chemical Communications 49:74, pages 8187.
Crossref
Crossref
Wolf-Dieter Janthur, Nathan Cantoni & Christoph Mamot. (2012) Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice. International Journal of Molecular Sciences 13:12, pages 16020-16045.
Crossref
Crossref
Beverly A. Teicher & James H. Doroshow. (2012) The Promise of Antibody–Drug Conjugates. New England Journal of Medicine 367:19, pages 1847-1848.
Crossref
Crossref